DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Market Closed - Deutsche Boerse AG 20:40:11 20/06/2024 BST | ||
| 35.96 EUR | +0.42% |
|
| Current month | +1.58% | ||
| 1 month | -2.34% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 35.96 | +0.42% |
| 19/06/24 | 35.81 | +0.28% |
| 18/06/24 | 35.71 | -0.36% |
| 17/06/24 | 35.84 | -0.88% |
| 14/06/24 | 36.16 | +0.06% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 08:40 pm
More quotesStatic data
| Product type | Discount-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN7LAQ |
| ISIN | DE000PN7LAQ3 |
| Date issued | 21/08/2023 |
| Maturity | 20/12/2024 (183 Days) |
| Parity | 1 : 1 |
| Emission price | 37.02 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.47 € |
|---|---|
| Lowest since issue | 34.83 € |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.04
USD
Average target price
53.19
USD
Spread / Average Target
+29.62%
- Stock Market
- Certificates
- Certificat
